Final Debarment Order: Angela Anatilde Baquero
FDA issued a final debarment order against Angela Anatilde Baquero, prohibiting her from providing services in any capacity to a drug product applicant or abbreviated drug application holder.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on July 31, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Low urgency. Drug product applicants and abbreviated drug application holders (branded, generic, API, contract manufacturers, and 503B outsourcing facilities) that may have employed or contracted with Angela Anatilde Baquero. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Immediately upon publication of the order (effective date of the order).. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
Angela Anatilde Baquero is now debarred by the FDA, meaning she cannot provide services in any capacity to a drug product applicant or abbreviated drug application holder.
Who it affects
Drug product applicants and abbreviated drug application holders (branded, generic, API, contract manufacturers, and 503B outsourcing facilities) that may have employed or contracted with Angela Anatilde Baquero.
What you must do
Review current and past employment/contractor relationships to ensure Angela Anatilde Baquero is not providing any services to your organization. If she is, terminate those services immediately.
Deadline
Immediately upon publication of the order (effective date of the order).
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- Novo Nordisk’s Bloomington Plant Receives FDA OAI Designation Following Contamination and Compliance Issues - pharmaceuticalcommerce.com
- Uyghur Forced Labor Prevention Act Entity List
- Final Debarment Order: Ricardo Andres Acuna
- Guidance: Biosimilar and Interchangeable Biosimilar Products: Considerations for Container Closure Systems and Device Constituent Parts
- Guidance: Assessing Adhesion with Transdermal and Topical Delivery Systems for Abbreviated New Drug Applications